An experienced team player to support development activities for new programs and manufacturing of product batches.
Taking the lead in developing clinical / regulatory strategies and managing our in-house and partnered product development programs.
Carduso Capital invests in PIMS-E, a Spin-off company of the University of Groningen that aims to develop an epinephrine dry powder inhaler as alternative to Epipen™. More info
I. Sibum, P. Hagedoorn, H.W. Frijlink, F. Grasmeijer International Journal of Pharmaceutics, 2019, 11 (5) (DOI: 10.3390/pharmaceutics11050233)
M. Luinstra, A.W.F. Rutgers, T. van Laar, F. Grasmeijer, A. Begeman, V. Isufi, L. Steenhuis, P. Hagedoorn, A.H. de Boer, H.W. Frijlink Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson’s disease, Therapeutic Advances in Chronic Disease, 2019, 10 More info
M. Luinstra, V. Isufi, L. de Jong, A.W.F. Rutgers, P. Hagedoorn, J. Puttenstein, T. van Laar, H.W. Frijlink International Journal of Pharmaceutics, 2019, 567, p. 1-5 https://doi.org/10.1016/j.ijpharm.2019.118493